Many tumors remain poorly infiltrated or functionally inaccessible to effective antitumor immunity.
MIORG Oy
Reverse translational immuno-oncology for partnering-ready therapeutic and diagnostic assets.
- Reverse translational precision oncology platform centered on immune-resistance biology in human tumors.
- Programs advanced through target discovery, validation, therapeutic design, and preclinical proof-of-concept.
- Business model focused on partnering-ready assets for licensing, collaboration, and broader pharmaceutical development.
Confidential target details are intentionally excluded from this public-safe overview.
Cancer immunotherapy resistance remains a major unmet need.
Immune checkpoint therapy changed oncology, but durable benefit remains constrained by cold tumors, immune-desert states, poor tumor immunogenicity, and disrupted innate-adaptive immune crosstalk that prevents effective antitumor responses.
Mechanisms that actively suppress immune control are not always captured by conventional discovery workflows.
Mechanism-based assets can create new combination logic and new routes to restoring antitumor immune activity.
From patient-derived discovery to partnering-ready assets
MIORG uses reverse translational precision oncology to start from human tumor biology, build more assertive preclinical programs, and create value before clinical execution.
MIORG starts with patient-derived discovery and advances assets through target validation, therapeutic design, functional and in vivo proof-of-concept, and IND-enabling / partnering preparation.
Patient-derived discovery
Human tumor biology, biospecimens, resistance phenotypes.
Target validation
Functional validation of actionable resistance biology.
Therapeutic design
Peptides, antibodies, and diagnostic-linked strategies.
Functional & in vivo PoC
Mechanism, immune restoration, tumor-model evidence.
IND-enabling / Partnering
Preclinical package, licensing, pharma partnering.
Preclinical PoC / IND-enabling / partnering-ready asset
Clinical development is shown to contextualize the full drug lifecycle; MIORG’s primary business model is preclinical asset generation and partnering.
Phase 1
First-in-human safety and dose escalation.
Phase 2
Efficacy signal and dose optimization.
Phase 3
Large-scale efficacy and safety confirmation.
Regulatory approval
Submission, review, approval.
Commercial launch
Market access, reimbursement, commercialization.
Platform workflow
A translation model built to move efficiently from patient-derived biology to partnering-ready preclinical packages.
Patient-derived discovery
Clinically annotated biospecimens and translational datasets reveal resistance mechanisms in tumors.
Target validation
Systems immunology and functional testing confirm biological relevance and tractability.
Therapeutic design
Programs are translated into peptide, antibody, and biomarker-guided therapeutic strategies.
Functional and in vivo PoC
Programs advance through mechanism-driven preclinical experiments and efficacy-supporting models.
Partnering pathway
Selected assets are positioned for licensing, partnering, or progression into broader development paths.
Therapeutic pipeline
| Program | Modality | Indication | Stage | Positioning |
|---|---|---|---|---|
| Invaritin (MIO-7436) | Therapeutic peptide | Cutaneous melanoma | In vivo PoC | Antigen-presentation-associated immune resistance |
| MIO-36 | Monoclonal antibody | Cutaneous melanoma and solid tumors | In vivo PoC / Lead Optimization | Innate immune engagement to drive adaptive antitumor immunity |
| Nexorin (MIO-7071) | Therapeutic peptide | Melanoma and solid tumors | Discovery | Immune-receptor-associated resistance |
| Nexlimomab (MIO-7072) | Monoclonal antibody | Melanoma and solid tumors | Discovery / Lead Optimization | Immune-receptor-associated resistance |
Companion diagnostics pipeline
| Program | Type | Indication | Stage | Technology |
|---|---|---|---|---|
| MIORG PredictMLB Dx (MIO-2101) | Companion diagnostic / clinical decision-support tool | Cutaneous melanoma, non-small cell lung cancer, and breast cancer | Kit development | Targeted transcriptomic assay + algorithm |
| MIORG UvealMet Dx (MIO-5201) | Prognostic test | Uveal melanoma | Model development / retrospective validation | Targeted transcriptomic immune-metabolic assay + algorithm |
Lead programs illustrate the platform’s therapeutic and diagnostic logic.
Invaritin (MIO-7436)
- Designed to modulate antigen-presentation-associated immune resistance.
- Focused on restoring antitumor immune activity in melanoma contexts.
- Advancing through optimized preclinical proof-of-concept.
MIO-36
- Engages innate immune activity to drive adaptive antitumor immunity.
- Positioned for rational immunotherapy combinations in cold tumor settings.
- Advancing through in vivo proof-of-concept and lead optimization.
MIORG PredictMLB Dx (MIO-2101)
- Supports response stratification in metastatic cutaneous melanoma.
- Uses targeted transcriptomic signatures and algorithmic modeling.
- Provides a supporting biomarker layer for therapy-focused development.
MIORG UvealMet Dx (MIO-5201)
- Targets prognostic stratification in uveal melanoma.
- Built around immune-metabolic tumor signatures and algorithmic interpretation.
- Can create both clinical utility and strategic partnering relevance.
Preclinical asset generation designed for licensing and pharma partnering.
MIORG creates value before clinical execution by moving from patient-derived discovery to functionally validated therapeutic and diagnostic assets with clear partner development pathways.
- Discover immune-resistance targets from patient-derived tumor biology.
- Validate functional relevance in tumor immunogenicity and antitumor immune responses.
- Generate therapeutic peptide, monoclonal antibody, and diagnostic assets.
- Advance selected programs toward partnering-ready preclinical packages.
- Licensing of individual programs or program families.
- Therapeutic or diagnostic co-development collaborations.
- Progression into IND-enabling development with pharmaceutical partners.
- Program positioning supported by biomarker-informed patient selection logic.
Large oncology markets are converging around immunotherapy, biomarkers, and AI-enabled discovery.
Projected worldwide oncology drugs revenue by 2030, up from US$232.50bn in 2026.
Projected global cancer immunotherapy market size by 2031, compared with US$83.6bn in 2023.
Projected global AI drug discovery market size by 2032, supporting faster asset generation.
- Immunotherapy resistance creates demand for rational combinations that expand responder populations.
- Biomarker-guided development supports clearer patient-selection and partnering logic.
- AI-enabled discovery and molecular design can improve preclinical asset generation efficiency.
MIORG team
Founder-led translational immuno-oncology supported by scientific, clinical, business, and strategic advisory expertise relevant to preclinical asset generation and pharma partnering.
Scientific leadership, partnerships, and commercial perspective supporting MIORG’s execution model.
Founder & Scientific Director
Cancer immunology, reverse translational precision oncology, therapeutic and diagnostic program leadership.
Head of Strategic Partnerships & Co-Founder
Strategic partnerships, stakeholder engagement, behavioral science, operations and growth support.
Business Development & Market Intelligence
Market research, customer acquisition, investor relations, and growth strategy.
Chief Scientific Officer
Scientific program development, translational research strategy, and preclinical execution support.
External expertise spanning pathology, translational medicine, clinical strategy, fundraising, and governance.
Senior Advisor, Translational Pathology
Clinical pathology, translational oncology, biomarker validation, and tissue pathology strategy.
Clinical Advisor (UK and EU)
Clinical oncology and translational immuno-oncology guidance.
Clinical Advisor (USA)
Melanoma-focused clinical insight and therapeutic development perspective.
Senior Advisor, Translational Medicine
Translational medicine, biomarker strategy, and immune profiling perspective.
Fundraising Advisor
Financing strategy and investor-facing development support.
Advisor, Growth & Investment Strategy
Growth planning, investment strategy, and external positioning.
Advisor, Corporate Strategy & Governance
Corporate strategy, governance, and scaling perspective.
Near-term milestones
Advance selected peptide and monoclonal antibody programs through functional and in vivo proof-of-concept.
Continue retrospective validation, assay refinement, and positioning of transcriptomic diagnostic tools for partnering.
Build data packages that support investor discussions, strategic collaborations, and later-stage preclinical development planning.
Partnering and investor contact
MIORG welcomes conversations with investors, pharmaceutical companies, diagnostic partners, and translational collaborators interested in preclinical immunotherapy assets and reverse translational oncology.
- Therapeutic program partnering
- Diagnostic collaboration
- Investor outreach
- Preclinical development strategy